[1] He M, Wang J, Liang Q, et al. Time-restricted eating with or without low-carbohydrate diet reduces visceral fat and improves metabolic syndrome: A randomized trial[J]. Cell Reports Medicine, 2022, 3(10): 100777.

[2] Zhang M, Chong K K L, Chen Z, et al. Rapamycin improves Graves’ orbitopathy by suppressing CD4+ cytotoxic T lymphocytes[J]. JCI insight, 2023, 8(3).

[3] Choline and butyrate beneficially modulate the gut microbiome without affecting atherosclerosis in APOE*3-Leiden.CETP mice.Liu C, Li Z, Song Z, Fan X, Shao H, Sch枚nke M, Boon MR, Rensen PCN, Wang Y. Atherosclerosis. 2022 Dec;362:47-55. doi: 10.1016/j.atherosclerosis.2022.10.009. Epub 2022 Oct 19. Liu C Atherosclerosis 2022 2022/11/8 10.1016/j.atherosclerosis.2022.10.009 6.847

[4] Time-restricted eating with or without low-carbohydrate diet reduces visceral fat and improves metabolic syndrome: A randomized trial.He M, Wang J, Liang Q, Li M, Guo H, Wang Y, Deji C, Sui J, Wang YW, Liu Y, Zheng Y, Qian B, Chen H, Ma M, Su S, Geng H, Zhou WX, Guo X, Zhu WZ, Zhang M, Chen Z, Rensen PCN, Hui CC, Wang Y, Shi B. Cell Rep Med. 2022 Oct 18;3(10):100777. doi: 10.1016/j.xcrm.2022.100777. Epub 2022 Oct 10. He M Cell Rep Med 2022 2022/10/11 PMC9589024 10.1016/j.xcrm.2022.100777 16.988

[5] 调节胆固醇代谢治疗非酒精性脂肪性肝病的研究进展.延欢，王亚楠 延欢 中华临床营养杂志 2022 1.233

[6] Zhang M, Ding X, Wu L P, et al. A promising mouse model of graves' orbitopathy induced by adenovirus expressing thyrotropin receptor a subunit[J]. Thyroid, 2021, 31(4): 638-648.

[7] Hepatic Scavenger Receptor Class B Type 1 Knockdown Reduces Atherosclerosis and Enhances the Antiatherosclerotic Effect of Brown Fat Activation in APOE*3-Leiden.CETP Mice.Zhou E, Li Z, Nakashima H, Liu C, Ying Z, Foks AC, Berb茅e JFP, van Dijk KW, Rensen PCN, Wang Y. Arterioscler Thromb Vasc Biol. 2021 Apr;41(4):1474-1486. doi: 10.1161/ATVBAHA.121.315882. Epub 2021 Feb 11. Zhou E Arterioscler Thromb Vasc Biol 2021 2021/2/11 10.1161/ATVBAHA.121.315882 10.514

[8] Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice.Zhou E, Li Z, Nakashima H, Choukoud A, Kooijman S, Berb茅e JFP, Rensen PCN, Wang Y. Pharmacol Res. 2021 May;167:105524. doi: 10.1016/j.phrs.2021.105524. Epub 2021 Mar 2. Zhou E Pharmacol Res 2021 2021/3/5 10.1016/j.phrs.2021.105524 10.334